FRE

News

RECENT NEWS

Medexus to Present at the 2019 LD Micro Virtual Conference

Posted on March 8, 2019

MONTREAL, March 8, 2019 -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it will be presenting at the second annual LD Micro Virtual Conference on Tuesday, March 12th at 10:20 AM EST / 7:20 AM PST. Ken d’Entremont, Chief Executive Officer and Roland Boivin, Chief Financial Officer, of Medexus, will be giving the presentation and answering questions from investors. […]

Read more >
Medexus Granted Authorization by Health Canada to Distribute Treosulfan in Canada

Posted on March 6, 2019

MONTREAL, March XX, 2019 -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that Health Canada has authorized the Company to distribute Treosulfan, a conditioning agent used prior to stem cell transplantation. […]

Read more >
Medexus Enters into Expanded Licensing Agreement for Gliolan® in Canada

Posted on March 4, 2019

MONTREAL, March 4, 2019 -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it has entered into a licensing agreement with photonamic GmbH & Co. KG (“photonamic”) for the exclusive rights to market and distribute Gliolan® in Canada, which assists neurosurgeons to better visualize and more completely remove malignant brain tumors (gliomas) by causing them to become fluorescent and glow during surgery. […]

Read more >
Medexus Pharmaceuticals Announces 512% Increase in Revenue to $14.4 Million for the Third Quarter of Fiscal 2019

Posted on February 25, 2019

MONTREAL, February 25, 2019 -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today provided a business update and announced its operating and financial results for the fiscal third quarter ended December 31, 2018. All amounts are in Canadian dollars. […]

Read more >
Medexus Pharmaceuticals Schedules Third Quarter Fiscal 2019 Conference Call

Posted on February 13, 2019

MONTREAL, February 13, 2019 -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 4:30 PM Eastern Time on Monday, February 25, 2019 to discuss the Company’s financial results for the fiscal third quarter ended December 31, 2018, as well as the Company’s corporate progress and other developments. […]

Read more >
Medexus Lists October 2018 Unsecured Convertible Debentures on the TSX Venture Exchange

Posted on February 12, 2019

MONTREAL, February 12, 2019 -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company”) (TSXV: MDP, OTCQB: PDDPF) today announced that the 6.0% unsecured convertible debentures of the Company (the “Debentures”) will commence trading on the TSX Venture Exchange under the symbol “MDP.DB” at the market opening today, Tuesday, February 12, 2019. […]

Read more >
Medexus Files Business Acquisition Report

Posted on January 7, 2019

MONTREAL, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company”) (TSXV: MDP, OTCQB: PDDPF) today announced the filing of the Business Acquisition Report (“BAR”) on SEDAR (www.sedar.com) in relation to the previously announced transaction that occurred on October 16, 2018. “As can be seen in the unaudited interim financial statements (non-IFRS compliant) for the period ended Sept 30, 2018 included in the BAR, both Medexus Inc. and medac Pharma […]

Read more >
Medexus Announces New Chief Executive Officer, Chair of the Board of Directors, Other Organizational Updates and Equity Incentive Grants

Posted on December 17, 2018

MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company”) (TSXV: PDP, OTCQB: PDDPF) today announced organizational changes designed to better position the Company as it continues to integrate the transformative acquisitions of Medexus Inc. (“Medexus”) and medac Pharma, Inc. (“Medac Pharma”). ORGANIZATIONAL AND CORPORATE UPDATES The Company is pleased to announce that the board of directors of the Company (the “Board”) has appointed Ken d'Entremont […]

Read more >
Pediapharm Announces Name Change, Consolidation and Debenture Repayment

Posted on December 13, 2018

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. MONTREAL, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the "Company") (TSXV: PDP, OTCQB: PDDPF) is pleased to announce that at the annual general and special meeting of shareholders held on December 12, 2018 (the "Meeting"), the Company's shareholders approved the change […]

Read more >
Pediapharm Announces Q2 Results – Record Adjusted EBITDA, Record Revenue and 13th Consecutive Year-Over-Year Quarterly Revenue Growth

Posted on November 27, 2018

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. MONTREAL, Nov. 27, 2018 (GLOBE NEWSWIRE) — Pediapharm Inc. (the “Company” or “Pediapharm”) (TSXV: PDP, OTCQB: PDDPF) is pleased to file its second quarter financial […]

Read more >
Pediapharm Announces Closing of Transformative Acquisitions, Diversifying and Expanding the Platform for Future Growth

Posted on October 17, 2018

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. MONTREAL, Oct. 16, 2018 (GLOBE NEWSWIRE) — Pediapharm Inc. (“Pediapharm“) (TSXV: PDP, OTCQB: PDDPF) is pleased to announce the closing of its previously announced acquisitions […]

Read more >
Pediapharm Announces Closing of Subscription Receipt Offering for Total Gross Proceeds of $62 Million

Posted on October 12, 2018

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. MONTREAL, Oct. 11, 2018 (GLOBE NEWSWIRE) — Pediapharm Inc. (“Pediapharm“) (TSXV: PDP, OTCQB: PDDPF) is pleased to announce the closing today of its previously announced […]

Read more >
Pediapharm Files Corporate Presentation

Posted on September 12, 2018

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. MONTREAL, Sept. 12, 2018 (GLOBE NEWSWIRE) — Pediapharm Inc. (“Pediapharm“) (TSXV:PDP) (OTCQX:PDDPF) announces that, further to its press release issued on September 6, 2018, it […]

Read more >
Pediapharm Announces Transformative Acquisitions and $60 Million Offering of Subscription Receipts

Posted on September 7, 2018

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. MONTREAL, Sept. 06, 2018 (GLOBE NEWSWIRE) — Pediapharm Inc. (“Pediapharm“) (TSXV: PDP, OTCQX: PDDPF) is pleased to announce that it has entered into definitive agreements […]

Read more >
Pediapharm Announces Q1 Results – Record Revenue and 12th Consecutive Year-Over-Year Quarterly Growth

Posted on September 4, 2018

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MONTREAL, Aug. 27, 2018 (GLOBE NEWSWIRE) — Pediapharm Inc. (the “Company” or “Pediapharm”) (TSX VENTURE: PDP) (OTCQB: PDDPF) is pleased to file its first quarter financial results ended June 30, 2018. All dollar amounts are expressed in Canadian currency and results are […]

Read more >
Pediapharm Announces Annual Audited Financial Results – 61% Annual Revenue Growth and 11th Consecutive Year-over-year Quarterly Growth

Posted on July 18, 2018

MONTRÉAL, July 18, 2018 (GLOBE NEWSWIRE) — Pediapharm Inc. (the “Company” or “Pediapharm”) (TSX VENTURE:PDP) (OTCQB:PDDPF) is pleased to announce its annual audited results for the year ended March 31, 2018. All dollar amounts are expressed in Canadian currency and results are reported in accordance with IFRS accounting principles. KEY HIGHLIGHTS – PERIOD ENDED MARCH […]

Read more >
Pediapharm Announces the Commercial Launch of Cuvposa™ in Canada

Posted on April 3, 2018

MONTREAL, April 03, 2018 (GLOBE NEWSWIRE) — Pediapharm Inc. (the “Company” or “Pediapharm”) (TSX VENTURE:PDP) (OTCQB:PDDPF) is very pleased to announce the Canadian commercial launch of Cuvposa™ (Glycopyrrolate oral solution 1 mg/ 5 mL) which is indicated to reduce chronic severe drooling in patients aged 3-18 years with neurologic conditions associated with problem drooling (e.g. […]

Read more >
Pediapharm Announces Q3 Results – 10th Consecutive Year-over-year Quarterly Growth

Posted on February 27, 2018

MONTREAL, QUEBEC–(Marketwired – Feb. 27, 2018) – NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Pediapharm Inc. (the “Company” or “Pediapharm”) (TSX VENTURE:PDP)(OTCQB:PDDPF) is pleased to file its third quarter financial results ended December 31, 2017. All dollar amounts are expressed in Canadian currency and results are reported in […]

Read more >
Pediapharm Announces Extension of Debentures and Warrants

Posted on January 31, 2018

MONTREAL, QUEBEC–(Marketwired – Jan. 31, 2018) – NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Pediapharm Inc. (the “Company” or “Pediapharm”) (TSX VENTURE:PDP)(OTCQB:PDDPF) has proposed to amend its existing convertible secured debentures (the “Debentures”) and common share purchase warrants (“Warrants”) issued on March 30, 2015 with a maturity date […]

Read more >
Pediapharm Announces Q2 Record Revenue and First-Ever Adjusted Ebitda Positive Quarter

Posted on November 28, 2017

MONTREAL, QUEBEC–(Marketwired – Nov. 27, 2017) NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Pediapharm Inc. (TSX VENTURE:PDP)(the “Company” or “Pediapharm”) is pleased to file its second quarter financial results ended September 30, 2017. All dollar amounts are expressed in Canadian currency and results are reported in accordance with […]

Read more >